Your browser doesn't support javascript.
loading
Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis.
Maugeri, D; Panebianco, P; Rosso, D; Calanna, A; Speciale, S; Santangelo, A; Rizza, I; Motta, M; Lentini, A; Malaguarnera, M.
Afiliação
  • Maugeri D; Department of Senescent, Urological and Neurological Sciences, University of Catania, Via Messina 829, 95126 Catania, Italy. dmaugeri@tin.it
Arch Gerontol Geriatr ; 34(2): 117-22, 2002.
Article em En | MEDLINE | ID: mdl-14764315
ABSTRACT
The use of Alendronate for the treatment of senile diabetes with osteopenia or osteoporosis is a common practice today, although the reasons for the success of this treatment are not completely understood. We investigated 40 elderly female patients, over 70 years of age, divided in two Groups (A and B) 20 cases of each, with insulin-dependent senile diabetes and fair metabolic balance, with an average disease duration of 30 +/- 4 years. They all had osteoporosis shown by the mean T-score of bone mineral densitometry. The Groups were treated as follows, Group A with 10 mg/day of Alendronate per os, with morning fasting plus a supplementation of calcium and vitamin D3, while the Group B received only calcium and vitamin D3 per os. Bone mineral density (BMD) expressed in mg/cm2, and in terms of T-score and Z-score at the spine (L1-L4) was monitored over time after 12 and 24 months, using dexa technique with a Lunar DPX densitometer. Moreover, the variation of daily consumption of insulin (DCI) of all the study population was calculated 12 and 24 months after the start of treatments. The data of Group A showed an improvement of osteoporosis, as evidenced by the increase of BMD at both times of measurement, accompanied by a significant reduction in the DCI (-21.6% by the 12th month, and -36.2% by the end of the observation period). In the Group B only small, statistically insignificant changes were observed in both the BMD and DCI. The most plausible explanation of reduction of DCI in Group A seems to be that Alendronate has improved the clinical symptoms of osteoporosis (pain, rigidity, and reduction of movements) through its action on the bone mass recovery and slowing down the bone turnover and under these conditions the diabetic patients improved their own physical performance. The better and more extensive movements certainly produced a reduction in the DCI, since a correct and adequate physical activity does contribute to an improved glucose metabolism.
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Arch Gerontol Geriatr Ano de publicação: 2002 Tipo de documento: Article País de afiliação: Itália
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Arch Gerontol Geriatr Ano de publicação: 2002 Tipo de documento: Article País de afiliação: Itália